At MD Anderson, we work under the same roof as world-class physicians and researchers, providing unparalleled insights that guide each of our programs. We learn from those we treat, starting with a patient and their cancer in order to drive new therapeutics based on specific unmet needs.
To discover and develop effective new therapies, we have created state-of-the-art research platforms with industry-scale capabilities and collaborative teams of experts driven toward a singular goal: improving the lives of our patients.
Therapeutics Discovery Research Platforms
Discovering therapies to treat neurological disorders and cancer-related cognitive conditions
MD Anderson’s Cell Therapy Manufacturing Facility (CTMF) is a state-of-the-art laboratory which provides industrial drug-development expertise to advance cell therapy programs from laboratory concepts to commercializable therapeutics. Acquired in 2020, the CTMF is located just blocks from MD Anderson’s main hospital, making it an ideal facility to bring together the world-class research and unmatched clinical care that MD Anderson has to offer.
The CTMF is managed by MD Anderson’s Biologics Development team, part of the Therapeutics Discovery division. It is led by an experienced biopharmaceutical team with a combined 150 years of industry experience. The staff of industry veterans and MD Anderson scientists creates a unique culture of innovation and industrial good manufacturing practices (GMPs) with expertise in chimeric antigen receptor (CAR) T-cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, endogenous T-cell (ETC) therapy as well as other emerging and enabling cell-therapy modalities. The GMP facility boasts 11 clean rooms, 30,000 square feet of BSL-2+ clean rooms, and support space for Proof of Concept trials, pivotal trials and commercial launch, as needed. Additionally, three GMP clean rooms are located on a separate floor and serve as an ideal venue for viral vector manufacturing.
Biologics Development works closely with leading MD Anderson clinicians and researchers to help define the leading edge of cell therapies and rapidly advance products to patients and clinical proof-of-concept. Biologics Development also engages in strategic collaborations to co-develop innovative products, rapidly utilizing the expansive MD Anderson ecosystem.
Our collaborative agreements with leading pharmaceutical and biotechnology companies also are critical to our mission of advancing impactful therapies. These agreements can take a variety of forms based on how best to meet the needs of our patients.
By aligning with leading biopharmaceutical companies and strategic investors, we are able to combine the unique infrastructure and drug development capabilities of Therapeutics Discovery with the novel therapeutics and expertise of our collaborators to accelerate new therapies to benefit patients.
Establishing new companies allows us to advance promising medicines discovered and developed by our teams with the managerial, operational and investment expertise of our strategic partners.
We have licensed novel therapeutics discovered within our platforms to companies committed to advancing these medicines toward patients in need, often collaborating for ongoing development and early-stage clinical trials.